P50 implies adverse clinical outcomes in pediatric acute respiratory distress syndrome by reflecting extrapulmonary

Yura Kim1, Jae Hwa Jung2, Ga Eun Kim3

  • 1Department of Pediatrics, Severance Children's Hospital, Institute of Allergy, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, 50-1, Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.

Scientific Reports
|August 11, 2022
PubMed

Insights

In pediatric acute respiratory distress syndrome (PARDS), higher P50 levels, indicating reduced hemoglobin-oxygen affinity, correlate with increased organ dysfunction and mortality risk. This suggests P50 may aid in stratifying PARDS patient outcomes.

Area of Science:

  • Pediatric Critical Care Medicine
  • Respiratory Physiology
  • Hemoglobin-Oxygen Affinity

Background:

  • Pediatric acute respiratory distress syndrome (PARDS) is a critical condition associated with high mortality.
  • Hypoxemia and multiple organ dysfunction are key factors contributing to PARDS mortality.
  • Altered hemoglobin-oxygen affinity (P50) may impact tissue oxygenation and organ function in PARDS.

Purpose of the Study:

  • To evaluate P50 levels in pediatric patients with PARDS.
  • To determine the association between P50 and clinical outcomes, including organ dysfunction and mortality.

Main Methods:

  • Retrospective study of 212 children with PARDS requiring mechanical ventilation.
  • P50 levels calculated using Doyle's method.
  • Organ dysfunction assessed with the Pediatric Logistic Organ Dysfunction-2 score.

Main Results:

  • P50 levels increased significantly with increasing PARDS severity.
  • A positive association was found between P50 and extrapulmonary organ dysfunction score.
  • Higher P50 was significantly associated with increased risk of mortality, largely mediated by organ dysfunction.

Conclusions:

  • Elevated P50 at PARDS diagnosis may indicate increased mortality risk, primarily through extrapulmonary organ dysfunction.
  • P50 could serve as a potential biomarker for risk stratification in PARDS patients.
  • Further research is warranted to explore P50's role in managing PARDS.

Related Concept Videos

Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
334
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
298
Acute Respiratory Failure-IV01:23

Acute Respiratory Failure-IV

Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
208
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
299
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
191
Pulmonary Cycle: Exhalation01:17

Pulmonary Cycle: Exhalation

In terms of human respiration, the act of expelling air, known as exhalation (or expiration), operates on the principle of pressure gradients. During expiration, the pressure within the lungs exceeds that of the surrounding atmosphere. Under normal conditions, quiet breathing involves passive exhalation and is free of muscular contractions. This is because the exhalation process is driven by the natural elastic recoil of the lungs and chest wall, both of which have an inherent tendency to...
1.7K